Walleye Capital LLC Invests $641,000 in Royalty Pharma plc (NASDAQ:RPRX)

Walleye Capital LLC bought a new position in Royalty Pharma plc (NASDAQ:RPRX - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 25,124 shares of the biopharmaceutical company's stock, valued at approximately $641,000.

A number of other hedge funds also recently made changes to their positions in the company. Swedbank AB lifted its position in shares of Royalty Pharma by 10.3% in the fourth quarter. Swedbank AB now owns 12,164,170 shares of the biopharmaceutical company's stock worth $310,308,000 after buying an additional 1,136,800 shares in the last quarter. Geode Capital Management LLC grew its stake in Royalty Pharma by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 7,312,551 shares of the biopharmaceutical company's stock worth $186,846,000 after purchasing an additional 46,765 shares in the last quarter. Norges Bank bought a new position in Royalty Pharma in the fourth quarter worth approximately $124,498,000. Charles Schwab Investment Management Inc. grew its stake in Royalty Pharma by 4.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 3,131,628 shares of the biopharmaceutical company's stock worth $79,888,000 after purchasing an additional 130,025 shares in the last quarter. Finally, New South Capital Management Inc. lifted its holdings in Royalty Pharma by 19.9% during the fourth quarter. New South Capital Management Inc. now owns 2,957,125 shares of the biopharmaceutical company's stock worth $75,436,000 after buying an additional 490,754 shares during the period. 54.35% of the stock is currently owned by hedge funds and other institutional investors.

Royalty Pharma Stock Up 1.1 %

Shares of RPRX stock traded up $0.34 during trading hours on Monday, reaching $32.54. 3,256,591 shares of the company's stock were exchanged, compared to its average volume of 3,259,800. Royalty Pharma plc has a 1 year low of $24.05 and a 1 year high of $34.20. The stock has a market cap of $18.76 billion, a PE ratio of 22.44, a PEG ratio of 2.31 and a beta of 0.50. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 0.64. The stock's fifty day moving average price is $32.52 and its two-hundred day moving average price is $29.48.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last issued its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 EPS for the quarter, beating analysts' consensus estimates of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. Research analysts predict that Royalty Pharma plc will post 4.49 EPS for the current year.

Royalty Pharma Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th will be given a $0.22 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $0.88 annualized dividend and a yield of 2.70%. Royalty Pharma's dividend payout ratio is presently 60.69%.

Wall Street Analyst Weigh In

Separately, Citigroup restated a "buy" rating on shares of Royalty Pharma in a report on Friday, March 28th. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Royalty Pharma has an average rating of "Buy" and an average target price of $42.50.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.